Nε-(carboxymethyl) lysine-induced mitochondrial fission and mitophagy cause decreased insulin secretion from β-cells

Am J Physiol Endocrinol Metab. 2015 Nov 15;309(10):E829-39. doi: 10.1152/ajpendo.00151.2015. Epub 2015 Sep 22.

Abstract

Nε-(carboxymethyl) lysine-conjugated bovine serum albumin (CML-BSA) is a major component of advanced glycation end products (AGEs). We hypothesised that AGEs reduce insulin secretion from pancreatic β-cells by damaging mitochondrial functions and inducing mitophagy. Mitochondrial morphology and the occurrence of autophagy were examined in pancreatic islets of diabetic db/db mice and in the cultured CML-BSA-treated insulinoma cell line RIN-m5F. In addition, the effects of α-lipoic acid (ALA) on mitochondria in AGE-damaged tissues were evaluated. The diabetic db/db mouse exhibited an increase in the number of autophagosomes in damaged mitochondria and receptor for AGEs (RAGE). Treatment of db/db mice with ALA for 12 wk increased the number of mitochondria with well-organized cristae and fewer autophagosomes. Treatment of RIN-m5F cells with CML-BSA increased the level of RAGE protein and autophagosome formation, caused mitochondrial dysfunction, and decreased insulin secretion. CML-BSA also reduced mitochondrial membrane potential and ATP production, increased ROS and lipid peroxide production, and caused mitochondrial DNA deletions. Elevated fission protein dynamin-related protein 1 (Drp1) level and mitochondrial fragmentation demonstrated the unbalance of mitochondrial fusion and fission in CML-BSA-treated cells. Additionally, increased levels of Parkin and PTEN-induced putative kinase 1 protein suggest that fragmented mitochondria were associated with increased mitophagic activity, and ALA attenuated the CML-BSA-induced mitophage formation. Our study demonstrated that CML-BSA induced mitochondrial dysfunction and mitophagy in pancreatic β-cells. The findings from this study suggest that increased concentration of AGEs may damage β-cells and reduce insulin secretion.

Keywords: advanced glycated end products; diabetes; mitochondrial dynamics; mitophagy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antioxidants / metabolism
  • Antioxidants / therapeutic use
  • Biomarkers / metabolism
  • Cell Line, Tumor
  • Diabetes Mellitus / diet therapy
  • Diabetes Mellitus / metabolism*
  • Diabetes Mellitus / pathology
  • Dietary Supplements
  • Down-Regulation / drug effects
  • Glycation End Products, Advanced / antagonists & inhibitors
  • Glycation End Products, Advanced / metabolism*
  • Glycation End Products, Advanced / pharmacology
  • Insulin / metabolism*
  • Insulin Secretion
  • Insulin-Secreting Cells / drug effects
  • Insulin-Secreting Cells / metabolism*
  • Insulin-Secreting Cells / ultrastructure
  • Lysine / analogs & derivatives*
  • Lysine / antagonists & inhibitors
  • Lysine / metabolism
  • Male
  • Mice, Inbred C57BL
  • Mice, Mutant Strains
  • Mitochondrial Dynamics* / drug effects
  • Mitophagy* / drug effects
  • Oxidants / antagonists & inhibitors
  • Oxidants / pharmacology
  • Phagosomes / drug effects
  • Phagosomes / metabolism
  • Phagosomes / ultrastructure
  • Rats
  • Receptor for Advanced Glycation End Products / agonists
  • Receptor for Advanced Glycation End Products / metabolism
  • Serum Albumin, Bovine / antagonists & inhibitors
  • Serum Albumin, Bovine / pharmacology
  • Thioctic Acid / metabolism
  • Thioctic Acid / therapeutic use

Substances

  • Ager protein, mouse
  • Antioxidants
  • Biomarkers
  • Glycation End Products, Advanced
  • Insulin
  • Oxidants
  • Receptor for Advanced Glycation End Products
  • advanced glycation end products-bovine serum albumin
  • Serum Albumin, Bovine
  • N(6)-carboxymethyllysine
  • Thioctic Acid
  • Lysine